A new nasal spray was developed at a Harvard University-affiliated hospital that appears to slow down the progression of Alzheimer's disease symptoms. "It can be given with other treatments," Dr.

ARS Pharmaceuticals is poised for a “blue sky opportunity,” in launching its epinephrine nasal spray, according to Leerink Partners.

Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis. Rhinology, 41(3), 167-174.

New research published in Advanced Materials reports a novel nasal spray for preventing respiratory infections. The spray works by forming a protective coating on the nasal cavity, ...